Emerging therapies for hepatitis C virus (Q37772514)

22 August 2017

1 reference

title

Emerging therapies for hepatitis C virus. (English)

1 reference

22 August 2017

1 reference

1 reference

Aybike Birerdinc

1

1 reference

PubMed ID

20629602

22 August 2017

Zobair M Younossi

series ordinal

2

1 reference

PubMed ID

20629602

22 August 2017

language of work or name

English

0 references

publication date

15 July 2010

1 reference

Expert Opinion on Emerging Drugs

22 August 2017

1 reference

22 August 2017

15

1 reference

22 August 2017

4

1 reference

22 August 2017

535-544

1 reference

Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Update on viral hepatitis: 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

The changing epidemiology and natural history of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

The way forward in HCV treatment--finding the right path

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Epidemiology of hepatitis C virus (HCV) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Effect of alpha interferon on the hepatitis C virus replicon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Replicative Homeostasis III: implications for antiviral therapy and mechanisms of response and non-response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Sequence diversity of hepatitis C virus: implications for immune control and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Viral Determinants of Resistance to Treatment in Patients with Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Prospective study on early virologic response to treatment with interferon alpha-2b plus ribavirin in patients with chronic hepatitis C genotype 1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Monoclonal and polyclonal antibodies against the HCV envelope proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Translation initiation by factor-independent binding of eukaryotic ribosomes to internal ribosomal entry sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Expression profiling reveals off-target gene regulation by RNAi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Novel inhibitors of hepatitis C virus RNA-dependent RNA polymerases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

HCV genetic variability: from quasispecies evolution to genotype classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

IFN-alpha receptor mRNA expression in a United States sample with predominantly genotype 1a/I chronic hepatitis C liver biopsies correlates with response to IFN therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Binding of the Hepatitis C Virus Envelope Protein E2 to CD81 Inhibits Natural Killer Cell Functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Dispensability and dynamics of caveolin-1 during liver regeneration and in isolated hepatic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

High relapse rate seen at week 72 for patients treated with R1626 combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.502527

10.1517/14728214.2010.502527

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20629602